CM Life Sciences, Inc. Announces Separate Trading of its Shares of Class A Common Stock and Warrants, on or about October 26, 2020

NEW YORK–(BUSINESS WIRE)–CM Life Sciences, Inc. (Nasdaq: CMLFU) (the “Company”) today announced that holders of the Company’s units sold in its initial public offering may elect to separately trade the shares of Class A common stock and redeemable warrants included in its units commencing on or about October 26, 2020. The shares of Class A … [Read more…]

FoundationOne®CDx Receives FDA-Approval as a Companion Diagnostic for VITRAKVI®(larotrectinib) to Identify Patients with NTRK Fusions Across All Solid Tumors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for VITRAKVI® (larotrectinib), which is currently FDA-approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) … [Read more…]

FDA Approves FoundationOne®CDx as Companion Diagnostic for Vitrakvi® (larotrectinib), to Aid in Identifying NTRK Fusion-Positive Patients

Detection of genomic alterations that drive the growth and spread of the tumor can guide treatment decisions for cancer therapies, including available biomarker driven treatments FoundationOne®CDx analyzes substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes as well as select rearrangements and genomic signatures across all solid tumors, including the … [Read more…]

Life Sciences Ontario Responds to Publication of Final PMPRB Guidelines

TORONTO–(BUSINESS WIRE)–LSO remains concerned by today’s release of the final PMPRB guidelines implementing the federal government’s patented medicine price controls. The final guidelines create a highly risky and uncertain pathway for commercializing new medicines and vaccines in Canada. LSO President and CEO Jason Field wants to ask the Government of Canada “why did it take … [Read more…]

Community Health Systems Completes Divestiture of San Angelo, Texas Hospital

FRANKLIN, Tenn.–(BUSINESS WIRE)–$CYH–Community Health Systems, Inc. (NYSE: CYH) announced today that a subsidiary of the Company has completed the sale of 171-bed San Angelo Community Medical Center in San Angelo, Texas, and its associated assets to subsidiaries of Shannon Health System. The effective date of the transaction is October 24, 2020. The hospital in this … [Read more…]

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced new hire grants totaling an aggregate of 58,800 inducement restricted stock awards (“RSAs”) to eleven employees. The RSAs vest over four years, with 25% of the underlying shares … [Read more…]

Vapotherm Announces Appointment of Donald Spence to Board of Directors and the Resignations of Craig Reynolds and Geoff Pardo

EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced the appointment of Donald Spence to the Company’s Board of Directors. Mr. Spence … [Read more…]

CUPE Says Rapid Testing at Calgary Airport a Solid Step, Calls for Other Airports to Follow Suit

CALGARY, Alberta–(BUSINESS WIRE)–CUPE 4070 is praising the announcement of rapid COVID testing at the Calgary airport. The union says the announcement is an important step to guide the industry through the pandemic without crashing. Chris Rauenbusch is President of CUPE 4070. He represents over 4,000 cabin crew members at the WestJet group of companies. “The … [Read more…]

PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine Candidate

A Philip Morris International subsidiary is a shareholder in a biopharmaceutical company that reached agreements with two departments of the Canadian government to accelerate its COVID-19 vaccine candidate efforts LAUSANNE, Switzerland–(BUSINESS WIRE)–Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which … [Read more…]